Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

NCT03153410 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Cyclophosphamide
DRUG: GVAX Pancreas Vaccine (GVAX)
DRUG: Pembrolizumab
DRUG: IMC-CS4

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]